HIPEC as Up-Front Treatment in Locally Advanced Ovarian Cancer.

PURPOSE

The main objective of the study is to evaluate the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of naïve ovarian cancer women undergoing complete or near-complete cytoreduction by assessing the overall survival, the disease-specific survival, and the disease-free survival. The secondary objective is the identification of prognostic indicators of survival and recurrence of these patients.

PATIENTS-METHODS: Retrospective study of treatment in naïve women with locally advanced ovarian cancer treated with cytoreductive surgery (CRS) and HIPEC and compared with those who were treated with cytoreduction alone. Clinicopathologic variables were correlated to overall survival, disease-specific survival, and disease-free survival using Kaplan-Meier method, and the multivariate Cox proportional hazards regression models.

RESULTS

5- and 10-year overall survival, disease-specific survival, and disease-free survival rates were significantly higher in patients treated with CRS and HIPEC. These patients were 67% less likely to die from any cause (adjusted hazard ratio, aHR = 0.33, = 0.001), 75% less likely to die from cancer (aHR = 0.25, = 0.003), and 46% less likely to develop recurrence (aHR = 0.54, = 0.041) compared to patients treated with CRS alone. Moreover, the poor performance status (aHR = 2.96, < 0.001), the serous carcinomas (aHR = 0.14, = 0.007), and the morbidity (aHR = 6.87, < 0.001) were identified as independent indicators of poor overall survival. The degree of differentiation (aHR = 8.64, = 0.003) was identified as the independent indicator of disease-specific survival (aHR = 4.13, = 0.002), while the extent of peritoneal carcinomatosis (aHR = 2.32, < 0.001) as the independent indicator of disease-free survival.

CONCLUSIONS

Treatment in naïve patients with locally advanced ovarian cancer undergoing CRS plus HIPEC appears to have improved overall, disease-specific, and disease-free survival.